Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2022 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

– Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 – – Topline results from...
May 11, 2022 13:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

– Data support the long-term safety and effectiveness of Zygel – – Greatest improvements seen in those with complete methylation of their FMR1 gene – DEVON, Pa., May 11, 2022 (GLOBE NEWSWIRE) --...
May 09, 2022 16:57 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

DEVON, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
May 02, 2022 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting

DEVON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
April 21, 2022 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting

DEVON, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
April 05, 2022 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

DEVON, Pa., April 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
March 22, 2022 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit

DEVON, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
March 01, 2022 06:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) – – Continued enrollment in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with FXS;...
February 28, 2022 16:05 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome

DEVON, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
February 28, 2022 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

DEVON, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...